Pick Topic
Review Topic
List Experts
Examine Expert
Save Expert
  Site Guide ··   
Spinal Diseases: HELP
Articles by Martin Rudwaleit
Based on 127 articles published since 2008
||||

Between 2008 and 2019, M. Rudwaleit wrote the following 127 articles about Spinal Diseases.
 
+ Citations + Abstracts
Pages: 1 · 2 · 3 · 4 · 5 · 6
1 Guideline Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force. 2018

Smolen, Josef S / Schöls, Monika / Braun, Jürgen / Dougados, Maxime / FitzGerald, Oliver / Gladman, Dafna D / Kavanaugh, Arthur / Landewé, Robert / Mease, Philip / Sieper, Joachim / Stamm, Tanja / Wit, Maarten de / Aletaha, Daniel / Baraliakos, Xenofon / Betteridge, Neil / Bosch, Filip van den / Coates, Laura C / Emery, Paul / Gensler, Lianne S / Gossec, Laure / Helliwell, Philip / Jongkees, Merryn / Kvien, Tore K / Inman, Robert D / McInnes, Iain B / Maccarone, Mara / Machado, Pedro M / Molto, Anna / Ogdie, Alexis / Poddubnyy, Denis / Ritchlin, Christopher / Rudwaleit, Martin / Tanew, Adrian / Thio, Bing / Veale, Douglas / Vlam, Kurt de / van der Heijde, Désirée. ·Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria. · 2nd Department of Medicine, Hietzing Hospital, Vienna, Austria. · Health Consult, Vienna, Austria. · Rheumazentrum Ruhrgebiet, Ruhr-University Bochum, Herne, Germany. · Department of Rheumatology, Paris Descartes University, Paris, France. · Department of Rheumatology, St Vincent's University Hospital, Dublin, Ireland. · Division of Rheumatology, University of Toronto, Toronto, Ontario, Canada. · Division of Rheumatology, University of California, San Diego, CA, USA. · Amsterdam Rheumatology & Immunology Center, Amsterdam, The Netherlands. · Division of Rheumatology Research, Swedish-Providence St. Joseph Health System, University of Washington, Seattle, WA, USA. · Department of Gastroenterology, Infectiology and Rheumatology, Campus Benjamin Franklin, Charité Universitätsmedizin Berlin, Berlin, Berlin, Germany. · Section for Outcomes Research, Center for Medical Statistics, Informatics, and Intelligent Systems, Medical University of Vienna, Vienna, Austria. · Department of Medical Humanities, VU University Medical Centre, Amsterdam, The Netherlands. · Neil Betteridge Associates, UK. · Ghent University Hospital, Ghent, Belgium. · Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK. · Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, UK. · Department of Medicine, University of California, San Francisco, CA, USA. · Department of Rheumatology, UPMC Univ Paris 06, GRC-UPMC 08 (EEMOIS); AP-HP, Pitié Salpêtrière Hospital, Paris, France. · Institute of Molecular Medicine, University of Leeds, Leeds, UK. · Seayn Medical, Voorschoten, The Netherlands. · Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · University Health Network and University of Toronto, Toronto, Ontario, Canada. · University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, UK. · A.DI.PSO. (Associazione per la Difesa degli Psoriasici)-PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), Rome, Italy. · Centre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, UK. · Division of Rheumatology, Center for Clinical Epidemiology and Biostatistics, Perelman School of Medicine, University of Pennsylvania, Pennsylvania, PA, USA. · German Rheumatism Research Centrer, Berlin, Germany. · Allergy, Immunology and Rheumatology Division, University of Rochester Medical Center Rochester, New York, NY, USA. · Division of Internal Medicine and Rheumatology, Klinikum Bielefeld, Bielefeld, Germany. · Department of Dermatology, Medical University of Vienna, Vienna, Austria. · Department of Dermatology, Erasmus Medical Center, Erasmus University, Rotterdam, The Netherlands. · Department of Rheumatology, Klinikum Bielefeld, Bielefeld, Germany. · Division of Rheumatology, University Hospitals Leuven, Leuven, Belgium. · Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. ·Ann Rheum Dis · Pubmed #28684559.

ABSTRACT: Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert opinion, a task force of rheumatologists, dermatologists, patients and a health professional developed an update of the 2012 recommendations. These underwent intensive discussions, on site voting and subsequent anonymous electronic voting on levels of agreement with each item. A set of 5 overarching principles and 11 recommendations were developed and voted on. Some items were present in the previous recommendations, while others were significantly changed or newly formulated. The 2017 task force arrived at a single set of recommendations for axial and peripheral SpA, including psoriatic arthritis (PsA). The most exhaustive discussions related to whether PsA should be assessed using unidimensional composite scores for its different domains or multidimensional scores that comprise multiple domains. This question was not resolved and constitutes an important research agenda. There was broad agreement, now better supported by data than in 2012, that remission/inactive disease and, alternatively, low/minimal disease activity are the principal targets for the treatment of PsA. As instruments to assess the patients on the path to the target, the Ankylosing Spondylitis Disease Activity Score (ASDAS) for axial SpA and the Disease Activity index for PSoriatic Arthritis (DAPSA) and Minimal Disease Activity (MDA) for PsA were recommended, although not supported by all. Shared decision-making between the clinician and the patient was seen as pivotal to the process. The task force defined the treatment target for SpA as remission or low disease activity and developed a large research agenda to further advance the field.

2 Guideline 2016 update of the ASAS-EULAR management recommendations for axial spondyloarthritis. 2017

van der Heijde, Désirée / Ramiro, Sofia / Landewé, Robert / Baraliakos, Xenofon / Van den Bosch, Filip / Sepriano, Alexandre / Regel, Andrea / Ciurea, Adrian / Dagfinrud, Hanne / Dougados, Maxime / van Gaalen, Floris / Géher, Pál / van der Horst-Bruinsma, Irene / Inman, Robert D / Jongkees, Merryn / Kiltz, Uta / Kvien, Tore K / Machado, Pedro M / Marzo-Ortega, Helena / Molto, Anna / Navarro-Compàn, Victoria / Ozgocmen, Salih / Pimentel-Santos, Fernando M / Reveille, John / Rudwaleit, Martin / Sieper, Jochen / Sampaio-Barros, Percival / Wiek, Dieter / Braun, Jürgen. ·Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. · Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands. · Department of Rheumatology, Zuyderland Medical Center, Heerlen, The Netherlands. · Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany. · Department of Rheumatology, Ghent University and Ghent University Hospital, Ghent, Belgium. · NOVA Medical School, Universidade Nova de Lisboa, Lisboa, Portugal. · Department of Rheumatology, University Hospital Zurich, Zurich Switzerland. · Diakonhjemmet Hospital, Oslo, Norway. · Paris Descartes University, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris, Paris, France. · INSERM (U1153), PRES Sorbonne Paris-Cité, Paris, France. · Semmelweis University, Budapest, Hungary. · Department of Rheumatology, VU University Medical Center, Amsterdam, The Netherlands. · University of Toronto, Toronto, Ontario, Canada. · Patient Research Partner, Amsterdam, The Netherlands. · Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway. · Centre for Rheumatology & MRC Centre for Neuromuscular Diseases, University College London, London, UK. · NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals Trust, Leeds, UK. · Leeds Institute of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, UK. · Department of Rheumatology, University Hospital La Paz, IdiPaz, Madrid, Spain. · Division of Rheumatology, Department of Physical Medicine and Rehabilitation, Faculty of Medicine, Erciyes University, Kayseri, Turkey. · NOVA Medical School, NOVA University of Lisbon, Lisboa, Portugal. · The University of Texas-Health McGovern Medical School, Dallas, USA. · Klinikum Bielefeld, Bielefeld, Germany. · Gent University, Gent, Belgium. · Charité University Medicine, Berlin, Germany. · Department of Rheumatology, Campus Benjamin Franklin, Charité, Berlin, Germany. · Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil. · EULAR PARE Patient Research Partner and Chair of EULAR PARE, Berlin, Germany. ·Ann Rheum Dis · Pubmed #28087505.

ABSTRACT: To update and integrate the recommendations for ankylosing spondylitis and the recommendations for the use of tumour necrosis factor inhibitors (TNFi) in axial spondyloarthritis (axSpA) into one set applicable to the full spectrum of patients with axSpA. Following the latest version of the European League Against Rheumatism (EULAR) Standardised Operating Procedures, two systematic literature reviews first collected the evidence regarding all treatment options (pharmacological and non-pharmacological) that were published since 2009. After a discussion of the results in the steering group and presentation to the task force, overarching principles and recommendations were formulated, and consensus was obtained by informal voting. A total of 5 overarching principles and 13 recommendations were agreed on. The first three recommendations deal with personalised medicine including treatment target and monitoring. Recommendation 4 covers non-pharmacological management. Recommendation 5 describes the central role of non-steroidal anti-inflammatory drugs (NSAIDs) as first-choice drug treatment. Recommendations 6-8 define the rather modest role of analgesics, and disprove glucocorticoids and conventional synthetic disease-modifying antirheumatic drugs (DMARDs) for axSpA patents with predominant axial involvement. Recommendation 9 refers to biological DMARDs (bDMARDs) including TNFi and IL-17 inhibitors (IL-17i) for patients with high disease activity despite the use (or intolerance/contraindication) of at least two NSAIDs. In addition, they should either have an elevated C reactive protein and/or definite inflammation on MRI and/or radiographic evidence of sacroiliitis. Current practice is to start with a TNFi. Switching to another TNFi or an IL-17i is recommended in case TNFi fails (recommendation 10). Tapering, but not stopping a bDMARD, can be considered in patients in sustained remission (recommendation 11). The final two recommendations (12, 13) deal with surgery and spinal fractures. The 2016 Assessment of SpondyloArthritis international Society-EULAR recommendations provide up-to-date guidance on the management of patients with axSpA.

3 Guideline [Treat-to-target (T2T) recommendation for patients with spondyloarthritis - translation into German]. 2016

Kiltz, U / Sieper, J / Backhaus, M / Buss, B / Gromnica-Ihle, E / Haíbel, H / Hammel, L / Karberg, K / Rehart, S / Rudwaleit, M / Schuch, F / Steffens-Korbanka, P / Braun, J. ·Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. uta.kiltz@elisabethgruppe.de. · Campus Benjamin Franklin, Charité Berlin, Hindenburgdamm 30, 12203, Berlin, Deutschland. · Park-Klinik Weissensee, Berlin, Deutschland. · Deutsche Rheuma-Liga, Maximilianstr. 14, 53111, Bonn, Deutschland. · Deutsche Vereinigung Morbus Bechterew e. V., Metzgergasse 16, 97421, Schweinfurt, Deutschland. · Praxis für Rheumatologie und Innere Medizin, Schlosstrasse 110, Berlin, Deutschland. · Agaplesion Markus Krankenhaus, Klinik für Orthopädie und Unfallchirurgie, Wilhelm-Epstein Str. 4, Frankfurt, Deutschland. · Klinikum Bielefeld Rosenhöhe, Bielefeld, Deutschland. · Rheumatologische Schwerpunktpraxis Erlangen, Möhrendorfer Str. 1c, Erlangen, Deutschland. · Rheumapraxis an der Hase, Osnabrück, Deutschland. · Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. ·Z Rheumatol · Pubmed #27488447.

ABSTRACT: The management of patients with spondyloarthritis (SpA) has experienced a paradigm shift in recent years. This is true for the treatment of axial as well as peripheral manifestations. International treat to target (T2T) recommendations for SpA based on the T2T strategy have now also been published, which contain 5 higher level principles (A-E) in addition to the 15 recommendations. In order to make the recommendations known and to promote national distribution, German experts have now issued a translation of the T2T recommendations for SpA into German.

4 Guideline EULAR recommendations for the use of imaging in the diagnosis and management of spondyloarthritis in clinical practice. 2015

Mandl, P / Navarro-Compán, V / Terslev, L / Aegerter, P / van der Heijde, D / D'Agostino, M A / Baraliakos, X / Pedersen, S J / Jurik, A G / Naredo, E / Schueller-Weidekamm, C / Weber, U / Wick, M C / Bakker, P A C / Filippucci, E / Conaghan, P G / Rudwaleit, M / Schett, G / Sieper, J / Tarp, S / Marzo-Ortega, H / Østergaard, M / Anonymous6530825. ·Division of Rheumatology, Medical University of Vienna, Vienna, Austria. · Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands University Hospital La Paz, Madrid, Spain. · Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Copenhagen University Hospital at Glostrup, Copenhagen, Denmark. · Public Health Department, Ambroise Paré Hospital, Boulogne-Billancourt, France. · Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. · Department of Rheumatology, Ambroise Paré Hospital, Boulogne-Billancourt, France. · Rheumazentrum Ruhrgebiet, Herne, Germany. · Department of Rheumatology, Copenhagen University Hospital at Gentofte, Copenhagen, Denmark. · Department of Radiology, Aarhus University Hospital, Aarhus, Denmark. · Department of Rheumatology, Hospital General Universitario Gregorio Marañón, Madrid, Spain. · Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria. · King Christian 10th Hospital for Rheumatic Diseases, Gråsten, Denmark. · Department of Radiology, Karolinska University Hospital, Stockholm, Sweden. · Department of Rheumatology, Università Politecnica delle Marche, Ancona, Italy. · NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK. · Department of Rheumatology, Charité Universitätsmedizin, Berlin, Germany. · Department of Rheumatology and Immunology, University of Erlangen-Nuremberg, Erlangen, Germany. · Musculoskeletal Statistics Unit, Department of Rheumatology, The Parker Institute, Copenhagen University Hospital, Bispebjerg and Frederiksberg, Copenhagen, Denmark. ·Ann Rheum Dis · Pubmed #25837448.

ABSTRACT: A taskforce comprised of an expert group of 21 rheumatologists, radiologists and methodologists from 11 countries developed evidence-based recommendations on the use of imaging in the clinical management of both axial and peripheral spondyloarthritis (SpA). Twelve key questions on the role of imaging in SpA were generated using a process of discussion and consensus. Imaging modalities included conventional radiography, ultrasound, magnetic resonance imaging, computed tomography (CT), positron emission tomography, single photon emission CT, dual-emission x-ray absorptiometry and scintigraphy. Experts applied research evidence obtained from systematic literature reviews using MEDLINE and EMBASE to develop a set of 10 recommendations. The strength of recommendations (SOR) was assessed by taskforce members using a visual analogue scale. A total of 7550 references were identified in the search process, from which 158 studies were included in the systematic review. Ten recommendations were produced using research-based evidence and expert opinion encompassing the role of imaging in making a diagnosis of axial SpA or peripheral SpA, monitoring inflammation and damage, predicting outcome, response to treatment, and detecting spinal fractures and osteoporosis. The SOR for each recommendation was generally very high (range 8.9-9.5). These are the first recommendations which encompass the entire spectrum of SpA and evaluate the full role of all commonly used imaging modalities. We aimed to produce recommendations that are practical and valuable in daily practice for rheumatologists, radiologists and general practitioners.

5 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8.4 Pharmaceutical therapy, 8.5 Evaluation of therapy success of pharmaceutical measures]. 2014

Kiltz, U / Sieper, J / Kellner, H / Krause, D / Rudwaleit, M / Chenot, J-F / Stallmach, A / Jaresch, S / Braun, J / Anonymous1960805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Deutschland, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181978.

ABSTRACT: -- No abstract --

6 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 8 Therapy, 8.1 Treatment concept, 8.2 Therapy targets and strategy]. 2014

Kiltz, U / Sieper, J / Rudwaleit, M / Kellner, H / Krause, D / Böhle, E / Böhm, H / Böhncke, W-H / Chenot, J-F / Heiligenhaus, A / Jaresch, S / Mau, W / Oberschelp, U / Pleyer, U / Repschläger, U / Schneider, E / Smolenski, U / Stallmach, A / Stemmer, M / Swoboda, B / Ulrich, C / Winking, M / Braun, J / Anonymous1920805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181976.

ABSTRACT: -- No abstract --

7 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 7 Disease activity and prognosis of spondyloarthritis]. 2014

Kiltz, U / Rudwaleit, M / Sieper, J / Krause, D / Oberschelp, U / Schneider, E / Swoboda, B / Böhm, H / Braun, J / Anonymous1900805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), Berlin, Deutschland, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181975.

ABSTRACT: -- No abstract --

8 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 6 Diagnostics]. 2014

Kiltz, U / Rudwaleit, M / Sieper, J / Krause, D / Hermann, K-G / Braun, J / Anonymous1910805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181974.

ABSTRACT: -- No abstract --

9 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 5 Initial diagnosis/referral strategy]. 2014

Kiltz, U / Rudwaleit, M / Sieper, J / Krause, D / Heiligenhaus, A / Pleyer, U / Chenot, J-F / Stallmach, A / Jaresch, S / Oberschelp, U / Schneider, E / Swoboda, B / Böhm, H / Hermann, K-G / Böhncke, W-H / Braun, J / Anonymous1890805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181973.

ABSTRACT: -- No abstract --

10 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 4 Classification and diagnostic criteria]. 2014

Kiltz, U / Rudwaleit, M / Sieper, J / Braun, J / Anonymous1870805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181972.

ABSTRACT: -- No abstract --

11 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 3 Clinical symptoms]. 2014

Kiltz, U / Rudwaleit, M / Sieper, J / Krause, D / Chenot, J-F / Stallmach, A / Jaresch, S / Oberschelp, U / Schneider, E / Swoboda, B / Böhm, H / Heiligenhaus, A / Pleyer, U / Böhncke, W-H / Stemmer, M / Braun, J / Anonymous1880805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181971.

ABSTRACT: -- No abstract --

12 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 2 Preamble]. 2014

Kiltz, U / Sieper, J / Rudwaleit, M / Kellner, H / Krause, D / Böhle, E / Böhm, H / Böhncke, W-H / Chenot, J-F / Heiligenhaus, A / Hermann, K-G / Jaresch, S / Mau, W / Oberschelp, U / Pleyer, U / Repschläger, U / Schneider, E / Smolenski, U / Stallmach, A / Stemmer, M / Swoboda, B / Ulrich, C / Winking, M / Braun, J / Anonymous1860805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181970.

ABSTRACT: -- No abstract --

13 Guideline [German Society for Rheumatology S3 guidelines on axial spondyloarthritis including Bechterew's disease and early forms: 1 Introduction/preliminary comments]. 2014

Kiltz, U / Sieper, J / Rudwaleit, M / Kellner, H / Krause, D / Böhle, E / Böhm, H / Böhncke, W-H / Chenot, J-F / Heiligenhaus, A / Hermann, K-G / Jaresch, S / Mau, W / Oberschelp, U / Pleyer, U / Repschläger, U / Schneider, E / Smolenski, U / Stallmach, A / Stemmer, M / Swoboda, B / Ulrich, C / Winking, M / Braun, J / Anonymous1850805. ·Deutsche Gesellschaft für Rheumatologie (DGRh), -, -, Uta.Kiltz@elisabethgruppe.de. ·Z Rheumatol · Pubmed #25181969.

ABSTRACT: -- No abstract --

14 Guideline [ASAS classification criteria for axial spondyloarthritis]. 2009

Rudwaleit, M / Braun, J / Sieper, J / Anonymous1110636. ·Rheumatologie, Med. Klinik I, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, 12200, Berlin, Deutschland. martin.rudwaleit@charite.de ·Z Rheumatol · Pubmed #19680669.

ABSTRACT: -- No abstract --

15 Guideline The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. 2009

Sieper, J / Rudwaleit, M / Baraliakos, X / Brandt, J / Braun, J / Burgos-Vargas, R / Dougados, M / Hermann, K-G / Landewé, R / Maksymowych, W / van der Heijde, D. ·Rheumatology, Medizinische Klinik I, Charité - Campus Benjamin Franklin, Hindenburgdamm 30, 12200 Berlin, Germany. joachim.sieper@charite.de ·Ann Rheum Dis · Pubmed #19433414.

ABSTRACT: The field of spondyloarthritis (SpA) has experienced major progress in the last decade, especially with regard to new treatments, earlier diagnosis, imaging technology and a better definition of outcome parameters for clinical trials. In the present work, the Assessment in SpondyloArthritis international Society (ASAS) provides a comprehensive handbook on the most relevant aspects for the assessments of spondyloarthritis, covering classification criteria, MRI and x rays for sacroiliac joints and the spine, a complete set of all measurements relevant for clinical trials and international recommendations for the management of SpA. The handbook focuses at this time on axial SpA, with ankylosing spondylitis (AS) being the prototype disease, for which recent progress has been faster than in peripheral SpA. The target audience includes rheumatologists, trial methodologists and any doctor and/or medical student interested in SpA. The focus of this handbook is on practicality, with many examples of MRI and x ray images, which will help to standardise not only patient care but also the design of clinical studies.

16 Editorial The impact of cohort studies in spondyloarthritis. 2013

Rudwaleit, Martin. · ·Joint Bone Spine · Pubmed #23238001.

ABSTRACT: -- No abstract --

17 Editorial Effects of low-dose infliximab on spinal inflammation on magnetic resonance imaging in ankylosing spondylitis. 2010

Rudwaleit, Martin. · ·J Rheumatol · Pubmed #20675850.

ABSTRACT: -- No abstract --

18 Review [Spondyloarthritides]. 2017

Rudwaleit, M. ·Klinik für Innere Medizin und Rheumatologie, Klinikum Bielefeld Rosenhöhe, An der Rosenhöhe 27, 33647, Bielefeld, Deutschland. martin.rudwaleit@klinikumbielefeld.de. ·Z Rheumatol · Pubmed #29043434.

ABSTRACT: Spondyloarthritides (SpA) are inflammatory rheumatic diseases affecting the axial skeleton, peripheral joints and entheses, and also manifest at extraskeletal sites. According to the more recently introduced nomenclature, predominant axial SpA is distinguished from predominant peripheral SpA. Axial SpA is further divided into radiographic and nonradiographic axial SpA. Genetic factors are relevant, with HLA-B27 being most important. The interleukin 23/17 pathway seems to be relevant and points towards new therapeutic targets. Inflammatory back pain is the leading symptom in axial SpA and has certain characteristics. In addition, HLA-B27 and sacroiliitis on imaging are important for diagnosis. Therapy consists of physiotherapy, nonsteroidal anti-inflammatory drugs (first line) and biologicals (second line). Conventional disease-modifying antirheumatic drugs are effective only in peripheral arthritis.

19 Review [Uveitis in spondyloarthritis]. 2017

Rudwaleit, M / Walscheid, K / Heiligenhaus, A. ·Innere Medizin und Rheumatologie, Klinikum Bielefeld Rosenhöhe, An der Rosenhöhe 27, 33647, Bielefeld, Deutschland. martin.rudwaleit@klinikumbielefeld.de. · Augenabteilung und Ophtha Lab, St. Franziskus Hospital, Münster, Deutschland. · Universität Duisburg-Essen, Essen, Deutschland. ·Z Rheumatol · Pubmed #28812149.

ABSTRACT: Acute anterior uveitis (AAU) is the most frequent uveitis subtype. It is often associated with HLA-B27 and with inflammatory rheumatic diseases, in particular with spondyloarthritis (SpA), which itself is strongly associated with HLA-B27. About 40-60% of patients with AAU have an associated spondyloarthritis, and 20-40% of patients with spondyloarthritis also have uveitis. The incidence of AAU in patients with SpA clearly correlates with disease duration. The AAU has an acute onset, usually affects only one eye at a time, and shows a tendency for recurrence. Early therapy of AAU with topical steroids is relevant for good visual outcomes. Minimum duration of therapy of flares of AAU is 6-8 weeks in order to prevent early recurrency. The rate of local complications correlates with the rate of AAU flares and the visual outcome is often good. Refractory uveitis and frequent recurrencies of AAU may be treated with conventional disease-modifying antirheumatic drugs (DMARDs, such as sulfasalazine and methotrexate) and biologicals (e.g. TNF-alpha inhibitors). Any first episode of AAU diagnosed by an ophthalmologist should prompt referral to rheumatology for suspected SpA, particularly if rheumatic symptoms are present.

20 Review [Spondyloarthritides]. 2017

Rudwaleit, M. ·Klinik für Innere Medizin und Rheumatologie, Klinikum Bielefeld Rosenhöhe, An der Rosenhöhe 27, 33647, Bielefeld, Deutschland. martin.rudwaleit@klinikumbielefeld.de. ·Internist (Berl) · Pubmed #28593426.

ABSTRACT: Spondyloarthritides (SpA) are inflammatory rheumatic diseases affecting the axial skeleton, peripheral joints and entheses, and also manifest at extraskeletal sites. According to the more recently introduced nomenclature, predominant axial SpA is distinguished from predominant peripheral SpA. Axial SpA is further divided into radiographic and nonradiographic axial SpA. Genetic factors are relevant, with HLA-B27 being most important. The interleukin 23/17 pathway seems to be relevant and points towards new therapeutic targets. Inflammatory back pain is the leading symptom in axial SpA and has certain characteristics. In addition, HLA-B27 and sacroiliitis on imaging are important for diagnosis. Therapy consists of physiotherapy, nonsteroidal anti-inflammatory drugs (first line) and biologicals (second line). Conventional disease-modifying antirheumatic drugs are effective only in peripheral arthritis.

21 Review [Psoriatric Arthritis and Spondyloartritis: Treat to Target, Tight Control or New Treatments]. 2017

Rudwaleit, Martin. · ·Dtsch Med Wochenschr · Pubmed #28187486.

ABSTRACT: -- No abstract --

22 Review [Evidence-based recommendations on diagnostics and therapy of axial spondyloarthritis : S3 guidelines of the German Society of Rheumatology (DGRh) in cooperation with the Association of the Scientific Medical Societies in Germany (AWMF)]. 2017

Kiltz, U / Rudwaleit, M / Sieper, J / Braun, J. ·Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. Uta.kiltz@elisabethgruppe.de. · Klinik Rosenhöhe, Klinikum Bielefeld, Bielefeld, Deutschland. · Campus Benjamin-Franklin, Charité, Berlin, Deutschland. · Rheumazentrum Ruhrgebiet, Claudiusstr. 45, 44649, Herne, Deutschland. ·Z Rheumatol · Pubmed #27882408.

ABSTRACT: The clinical course of axial spondyloarthritis (SpA) is variable and characterized by chronic back pain and extraspinal manifestations, such as asymmetrical arthritis, dactylitis and enthesitis. Extra-articular manifestations in the eyes (anterior uveitis), skin (psoriasis) and intestines (chronic inflammatory bowel disease) are also frequent manifestations in patients with SpA. Due to the heterogeneity of disease manifestations and the partial concentration on structural alterations in the sacroiliac joints visible in X‑ray images, the diagnosis is often delayed for many years. An important step in the direction of improved early recognition of axial SpA was establishment of the Assessment of SpondyloArthritis International Society (ASAS) classification criteria published in 2009, which focused on the initally deep-seated back pain and chronicity in relatively young patients as well as the importance of magnetic resonance imaging and HLA B 27 determination in the early stages of the disease. In order to achieve the foundations for an effective and timely therapy of affected patients, in 2014 on the initiative of the German Society of Rheumatology, S3 guidelines on axial SpA including Bechterew's disease and early forms were formulated in cooperation with other specialist societies. This article gives an overview of the contents of the S3 guidelines on axial SpA.

23 Review Defining active sacroiliitis on MRI for classification of axial spondyloarthritis: update by the ASAS MRI working group. 2016

Lambert, Robert G W / Bakker, Pauline A C / van der Heijde, Désirée / Weber, Ulrich / Rudwaleit, Martin / Hermann, K G / Sieper, Joachim / Baraliakos, Xenofon / Bennett, Alex / Braun, Jürgen / Burgos-Vargas, Rubén / Dougados, Maxime / Pedersen, Susanne Juhl / Jurik, Anne Grethe / Maksymowych, Walter P / Marzo-Ortega, Helena / Østergaard, Mikkel / Poddubnyy, Denis / Reijnierse, Monique / van den Bosch, Filip / van der Horst-Bruinsma, Irene / Landewé, Robert. ·Department of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada. · Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands. · King Christian 10th Hospital for Rheumatic Diseases, Gråsten, Denmark South Jutland Hospital and Institute of Regional Health Services Research, University of Southern Denmark, Odense, Denmark. · Endokrinologikum Berlin and Charité University Medicine, Berlin, Germany. · Department of Radiology, Charité Universitätsmedizin, Berlin, Germany. · Charité Universitätsmedizin, Berlin, Germany. · Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany. · Defence Medical Rehabilitation Centre, Surry, UK. · Department of Rheumatology, Hospital General de México and Faculty of Medicine, Universidad Nacional Autónoma de México, Mexico City, Mexico. · Department of Rheumatology, Hôpital Cochin, Paris Descartes University, Clinical Epidemiology and Biostatistics, PRES Sorbonne Paris-Cité, Paris, France. · Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Glostrup, Denmark Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark. · Department of Radiology, Aarhus University Hospital, Aarhus, Denmark. · Department of Medicine, University of Alberta, Edmonton, Alberta, Canada. · Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Musculoskeletal Biomedical Research Unit, Leeds Teaching Hospitals NHS Trust, Leeds, UK. · Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands. · Ghent University Hospital, Ghent, Belgium. · Department of Rheumatology, VU University Medical Centre, Amsterdam, The Netherlands. · Amsterdam Rheumatology & Immunology Center, Academic Medical Center, Amsterdam, The Netherlands. ·Ann Rheum Dis · Pubmed #26768408.

ABSTRACT: OBJECTIVES: To review and update the existing definition of a positive MRI for classification of axial spondyloarthritis (SpA). METHODS: The Assessment in SpondyloArthritis International Society (ASAS) MRI working group conducted a consensus exercise to review the definition of a positive MRI for inclusion in the ASAS classification criteria of axial SpA. Existing definitions and new data relevant to the MRI diagnosis and classification of sacroiliitis and spondylitis in axial SpA, published since the ASAS definition first appeared in print in 2009, were reviewed and discussed. The precise wording of the existing definition was examined in detail and the data and a draft proposal were presented to and voted on by the ASAS membership. RESULTS: The clear presence of bone marrow oedema on MRI in subchondral bone is still considered to be the defining observation that determines the presence of active sacroiliitis. Structural damage lesions seen on MRI may contribute to a decision by the observer that inflammatory lesions are genuinely due to SpA but are not required to meet the definition. The existing definition was clarified adding guidelines and images to assist in the application of the definition. CONCLUSION: The definition of a positive MRI for classification of axial SpA should continue to primarily depend on the imaging features of 'active sacroiliitis' until more data are available regarding MRI features of structural damage in the sacroiliac joint and MRI features in the spine and their utility when used for classification purposes.

24 Review Treating axial and peripheral spondyloarthritis, including psoriatic arthritis, to target: results of a systematic literature search to support an international treat-to-target recommendation in spondyloarthritis. 2014

Schoels, M M / Braun, J / Dougados, M / Emery, P / Fitzgerald, O / Kavanaugh, A / Kvien, T K / Landewé, R / Luger, T / Mease, P / Olivieri, I / Reveille, J / Ritchlin, C / Rudwaleit, M / Sieper, J / Smolen, J S / Wit, M de / van der Heijde, D. ·2nd Department of Internal Medicine, Center for Rheumatic Diseases, Hietzing Hospital, , Vienna, Austria. ·Ann Rheum Dis · Pubmed #23740234.

ABSTRACT: BACKGROUND: Current recommendations for the management of axial spondyloarthritis (SpA) and psoriatic arthritis are to monitor disease activity and adjust therapy accordingly. However, treatment targets and timeframes of change have not been defined. An international expert panel has been convened to develop 'treat-to-target' recommendations, based on published evidence and expert opinion. OBJECTIVE: To review evidence on targeted treatment for axial and peripheral SpA, as well as for psoriatic skin disease. METHODS: We performed a systematic literature search covering Medline, Embase and Cochrane, conference abstracts and studies in http://www.clinicaltrials.gov. RESULTS: Randomised comparisons of targeted versus routine treatment are lacking. Some studies implemented treatment targets before escalating therapy: in ankylosing spondylitis, most trials used a decrease in Bath Ankylosing Spondylitis Disease Activity Index; in psoriatic arthritis, protocols primarily considered a reduction in swollen and tender joints; in psoriasis, the Modified Psoriasis Severity Score and the Psoriasis Area and Severity Index were used. Complementary evidence correlating these factors with function and radiographic damage at follow-up is sparse and equivocal. CONCLUSIONS: There is a need for randomised trials that investigate the value of treat-to-target recommendations in SpA and psoriasis. Several trials have used thresholds of disease activity measures to guide treatment decisions. However, evidence on the effect of these data on long-term outcome is scarce. The search data informed the expert committee regarding the formulation of recommendations and a research agenda.

25 Review Certolizumab pegol in axial spondyloarthritis. 2013

Song, In-Ho / Rudwaleit, Martin. ·Charité Universitätsmedizin Berlin, Medical Clinic I- Rheumatology, Berlin, Germany. ·Expert Rev Clin Immunol · Pubmed #24215406.

ABSTRACT: The axial spondyloarthritis (SpA) classification criteria cover both patients with ankylosing spondylitis and non-radiographic axial SpA. After failure of NSAIDs TNF-α-inhibitors (TNF-blockers) can be given to patients with active axial SpA. Until recently, the TNF-blockers infliximab, adalimumab, etanercept and golimumab are labeled for the treatment of active ankylosing spondylitis while for active nr-axSpA only adalimumab has been approved in Europe. The TNF-blocker certolizumab pegol has recently been evaluated in the RAPID-axSpA trial which is the first placebo-controlled randomized-controlled trial in the entire group of axial SpA. An elevated C-reactive protein and/ or evidence of bone marrow edema on MRI of the sacroiliac joints were required for inclusion in RAPID-axSpA, and patients could have been preexposed to TNF-blockers. The interesting data of this important trial in the context of the emerging therapeutic field of non-radiographic axial SpA therapy is discussed in this review.

Next